Session Information
Session Type: Abstract Submissions (ACR)
Background/Purpose: To explore, using data from participants enrolled in the progression cohort of the Osteoarthritis Initiative (OAI), the effects of conventional knee osteoarthritis (OA) pharmacological treatment and those of the SySADOA glucosamine and chondroitin sulfate (Glu/CS) on disease structural changes.
Methods: Six hundred knee OA subjects were included in a 24-consecutive-month follow-up study with annual knee X-rays and magnetic resonance imaging (MRI) of the most symptomatic (greatest WOMAC pain) knee. Participants were further stratified based on whether or not they received OA conventional pharmacological treatment and/or Glu/CS. The main outcomes were the loss of joint space width (JSW) and the loss of cartilage volume measured by MRI using a newly developed fully-automated system.
Results: Three hundred participants reported taking (+) (n=300) or not (-) (n=300) OA treatment (analgesic/NSAIDs) for 24 months, with or without Glu/CS. The +analgesic/NSAIDs subjects showed higher WOMAC scores (p<0.0001) and smaller JSW (p=0.013), reflecting a more severe disease at baseline vs. the ‑analgesic/NSAIDs participants. In the ‑analgesic/NSAIDs group, a reduction in the cartilage volume loss at 24 months in the medial central plateau (p=0.007 univariate and p=0.03 multivariate analysis) was found in those taking Glu/CS. In the +analgesic/NSAIDs group, the subjects receiving Glu/CS demonstrated less cartilage volume loss in the plateau at 12 months (p=0.05) and in the central plateau at 24 months (p=0.05). In addition, in the +analgesic/NSAIDs group, participants taking Glu/CS and having a JSW at baseline greater than the median (less severe disease) had less cartilage volume loss at both 12 and 24 months in the lateral plateau (p=0.02 and 0.03, respectively). By contrast, in all groups, no significant reduction in JSW over time was found.
Conclusion: In both the +analgesic/NSAIDs and ‑analgesic/NSAIDs groups, participants who received Glu/CS had reduced cartilage volume loss over 24 months mainly on the plateau when assessed with qMRI, arguing for a targeted DMOAD effect of Glu/CS, which could not be identified by X-ray alone.
Disclosure:
J. Martel-Pelletier,
ArthroLab,
4,
Bioiberica,
5;
C. Roubille,
None;
J. P. Raynauld,
ArthroLab,
5;
F. Abram,
ArthroLab,
3;
P. Dodin,
ArthroLab,
3;
M. Dorais,
ArthroLab,
5;
P. Delorme,
None;
J. P. Pelletier,
ArthroLab,
4,
Bioiberica,
5.
« Back to 2013 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-on-cartilage-volume-changes-over-time-of-conventional-treatment-and-of-glucosamine-and-chondroitin-sulfate-in-knee-osteoarthritis-patients-data-from-the-osteoarthritis-initiative-cohort/